기본 통계
| CIK | 1824893 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Surrozen, Inc. - Equity Warrant
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 14, 2026 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 6, 2026 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| May 6, 2026 |
Exhibit 99.1 Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 6, 2026 (GLOBE NEWSWIRE) - Surrozen, Inc. (“Surrozen” or the “Company”) (Nasda |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2026 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy St |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| March 31, 2026 |
PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-294542 $50,000,000 Common Stock —————————— We have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated March 23, 2026, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus. In accordance with the terms of the Sales Agreement, we |
|
| March 23, 2026 |
As filed with the U.S. Securities and Exchange Commission on March 23, 2026 As filed with the U.S. Securities and Exchange Commission on March 23, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30-1374889 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 23, 2026 |
SURROZEN OPERATING INC. Severance and Change in Control Plan Exhibit 10.8 SURROZEN OPERATING INC. Severance and Change in Control Plan Section 1. Introduction. The Surrozen Operating Inc. Severance and Change in Control Plan (the “Plan”) is hereby established by the Board of Directors of Surrozen Operating Inc. (the “Company”) effective as of January 23, 2026. The purpose of the Plan is to provide for the payment of severance and/or Change in Control (as de |
|
| March 23, 2026 |
As filed with the Securities and Exchange Commission on March 23, 2026 Registration No. |
|
| March 23, 2026 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Ca |
|
| March 23, 2026 |
Exhibit 99.1 Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN- |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| March 23, 2026 |
Surrozen, Inc. Nonstatutory Stock Option Grant Notice (2025 Equity Inducement Plan) Exhibit 10.7 Surrozen, Inc. Nonstatutory Stock Option Grant Notice (2025 Equity Inducement Plan) Surrozen, Inc. (the “Company”), pursuant to its 2025 Equity Inducement Plan (as may be amended and/or restated as of the Date of Grant set forth below, the “Plan”), has granted to the Optionholder a Nonstatutory Stock Option to purchase the number of shares of the Common Stock set forth below (the “Opt |
|
| March 23, 2026 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.0001 par value pe |
|
| March 23, 2026 |
SURROZEN, INC. COMMON STOCK SALES AGREEMENT Exhibit 1.2 SURROZEN, INC. COMMON STOCK SALES AGREEMENT March 23, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Surrozen, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the |
|
| January 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2026 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 7, 2025 |
Exhibit 99.1 Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., November 7, 2025 (GLOBE NEWSWIRE) - Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today |
|
| November 7, 2025 |
SUBLEASE EXTENSION AGREEMENT RECITALS AGREEMENT Exhibit 10.2 SUBLEASE EXTENSION AGREEMENT This SUBLEASE EXTENSION AGREEMENT (this “Extension Agreement”) is made as of May 15, 2025, by and between Surrozen Operating, Inc., a Delaware corporation (“Sublessor”), and Nura Bio, Inc., a Delaware corporation (“Sublessee”). RECITALS WHEREAS, Sublessor and Sublessee are parties to that certain Sublease dated as of April 16, 2024 (the “Sublease”), for ap |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 7, 2025 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| October 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 29, 2025 |
FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 29, 2025 |
SURROZEN, INC. COMMON STOCK SALES AGREEMENT Exhibit 1.1 SURROZEN, INC. COMMON STOCK SALES AGREEMENT August 29, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Surrozen, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during th |
|
| August 29, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-287434 PROSPECTUS SUPPLEMENT (To prospectus dated May 23, 2025) $50,000,000 Common Stock We have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated August 29, 2025, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and accom |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 8, 2025 |
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update Daniel Chao, M. |
|
| August 8, 2025 |
As filed with the U.S. Securities and Exchange Commission on August 8, 2025 As filed with the U.S. Securities and Exchange Commission on August 8, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30-1374889 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ |
|
| August 8, 2025 |
Surrozen, Inc. 2025 Equity Inducement Plan. Exhibit 99.1 Surrozen, Inc. 2025 Equity Inducement Plan Adopted by the Board of Directors: August 7, 2025 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Eligible Employees to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be gi |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| August 8, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe |
|
| May 21, 2025 |
May 21, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 21, 2025 |
May 21, 2025 Craig Parker President and Chief Executive Officer Surrozen, Inc. 171 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 Re: Surrozen, Inc. Registration Statement on Form S-3 Filed May 20, 2025 File No. 333-287434 Dear Craig Parker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requ |
|
| May 20, 2025 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 Surrozen, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Surrozen, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Surrozen, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and hav |
|
| May 20, 2025 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 SURROZEN, INC. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Surrozen, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Surrozen, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [● |
|
| May 20, 2025 |
Exhibit 4.4 SURROZEN, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certificate. 8 Section 2 |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025 Registration No. |
|
| May 20, 2025 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 Surrozen, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Surrozen, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Surrozen, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [● |
|
| May 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Ca |
|
| May 15, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 9, 2025 |
Exhibit 99.1 Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 9, 2025 (GLOBE NEWSWIRE) - Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today annou |
|
| May 9, 2025 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| May 1, 2025 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-286703 PROSPECTUS Up to 5,213,415 Shares of Common Stock Up to 1,373,000 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants Up to 3,293,207 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the proposed resale from time to time by the selling stockholders of: • Up to 5,213,415 shares of co |
|
| April 29, 2025 |
April 29, 2025 Craig Parker Chief Executive Officer Surrozen, Inc. 171 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 Re: Surrozen, Inc. Registration Statement on Form S-3 Filed April 23, 2025 File No. 333-286703 Dear Craig Parker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for a |
|
| April 29, 2025 |
April 29, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 24, 2025 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-278800 PROSPECTUS SUPPLEMENT (to the prospectus dated April 25, 2024) Up to 1,091,981 Shares of Common Stock Up to 40,000 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants Up to 2,363,258 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus supplement updates, amends and supplements the prospectus cont |
|
| April 23, 2025 |
As filed with the Securities and Exchange Commission on April 23, 2025 Registration No. |
|
| April 23, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Co |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy St |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 31, 2025 |
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates Exhibit 99.1 Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) - Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| March 31, 2025 |
Exhibit 107 Calculation of Filing Fee Table (Form Type) Form S-8 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe |
|
| March 31, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2025 As filed with the U.S. Securities and Exchange Commission on March 31, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30-1374889 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ |
|
| March 31, 2025 |
Exhibit 19.1 INSIDER TRADING POLICY August 12, 2021 Introduction This policy determines acceptable transactions in the securities of Surrozen, Inc. (the “Company” or “Surrozen”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publicly available (“inside information |
|
| March 31, 2025 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary description of the securities of Surrozen, Inc. and is based on the provisions of our Certificate of Incorporation, or the Certificate of Incorporation, our Bylaws, or the Bylaws, and the applicable provisions of the Delaware General Corporation |
|
| March 31, 2025 |
Collaboration Agreement, dated as of October 31, 2024, by and between Surrozen Inc. and TCGFB, Inc. Exhibit 10.28 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE COMPANY HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version TCGFB, INC. COLLABORATION AGREEMENT This Collaboration Agreement (this “Agreement”) is entered into as of October 31, 2024 (the “Effecti |
|
| March 28, 2025 |
Exhibit 10.4 SURROZEN, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 24, 2025, by and between Surrozen, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Secur |
|
| March 28, 2025 |
Form of Pre-Funded Warrant (March 2025). Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 28, 2025 |
Exhibit 10.1 SURROZEN, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 24, 2025, by and between Surrozen, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto and set forth on Annex B hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 28, 2025 |
Form of Series E Common Warrant. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 24, 2025 |
Exhibit 99.1 Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases Announces an oversubscribed financing of $175 million in gross proceed |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 24, 2025 |
Exhibit 99.2 Targeted Regeneration March 2025 Legal Disclaimers This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events o |
|
| February 14, 2025 |
EX-99.1 2 tm256261d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. Th |
|
| February 14, 2025 |
SRZN / Surrozen, Inc. / PERCEPTIVE ADVISORS LLC - EX-99.1 begin 644 ck0001669811-ex991.pdf M)5!$1BTQ+C<-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V%L@," P(#8Q,B W.3)=("]# M;VYT96YT>O[\[;K<\&F%]@]*[="G'"/]NM M[<4I6-U^E$[ B-/.IZ'Y3#L$\,=62%/BV.S8QL7(H-0<#XDQ7@=]A.]JJ3@ATAA/V4C M7)\%'KB^S:PRG=ZY*8V/I$<8#L+W>#/:3X42KBT1T*[#W4$&H54&3R -":[C M,5&F,YK&IF/ 78P"+/(LS>&:!F;9=YB:GX)6ZO5W.8K/C&<#M$(OYCBM3!M MQS'F<5I DI.'%&*AIJ:KGW.J!SD@OJ6>I,]>E%M$0U?*LFB$6.:7"OBQ1%$ |
|
| November 14, 2024 |
SRZN / Surrozen, Inc. / Alyeska Investment Group, L.P. Passive Investment SC 13G/A 1 alyeska-srzn093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Surrozen, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86889P208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 13, 2024 |
SRZN / Surrozen, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 srzn13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Surrozen, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86889P208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 8, 2024 |
SRZN / Surrozen, Inc. / GOLDMAN SACHS GROUP INC - SURROZEN GSCO FILING Q3 2024 Passive Investment SC 13G/A 1 SURROZEN.txt SURROZEN GSCO FILING Q3 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SURROZEN, INC. - (Name of Issuer) Common Stock, $0.0001 par value per share - (Title of Class of Securities) 86889P208 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| November 6, 2024 |
Surrozen Provides Third Quarter 2024 Financial Results and Business Update Exhibit 99.1 Surrozen Provides Third Quarter 2024 Financial Results and Business Update Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of preclinical ophthalmology product candidates to R&D pipeline Received $10 million milestone payment from Boehrin |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 1, 2024 |
SRZN / Surrozen, Inc. / StemPoint Capital LP - SC 13G Passive Investment SC 13G 1 tm2426887d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Surrozen, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 86889P208 (CUSIP Number) October 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| October 2, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of 10/1/2024, by and between HCP OYSTER POINT III LLC, a Delaware limited liability company (“Landlord”) and SURROZEN OPERATING, INC., a Delaware corporation (F/K/A Surrozen, Inc.) (“Tenant”). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated August 4, 20 |
|
| October 2, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 01, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| August 12, 2024 |
Surrozen Provides Second Quarter 2024 Financial Results and Business Update Surrozen Provides Second Quarter 2024 Financial Results and Business Update Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application of unique Targeted Protein Degradation technologies resulting in robust Wnt signal activation in bispecific antibodies based on the Company's SWEETS technology platform SOUTH SAN FRANCISCO, Calif. |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| May 8, 2024 |
Sublease Agreement, dated April 19, 2024, by and between Surrozen, Exhibit 10.1 SUBLEASE THIS SUBLEASE (this "Sublease") is dated for reference purposes as of April 16, 2024, and is made by and between Surrozen Operating, Inc., a Delaware corporation ("Sublessor"), and Nura Bio, Inc., a Delaware corporation ("Sublessee"). Sublessor and Sublessee hereby agree as follows: l. Recitals: This Sublease is made with reference to the fact that HCP Oyster Point III LLC, a |
|
| May 8, 2024 |
Surrozen Provides First Quarter 2024 Financial Results and Business Update Exhibit 99.1 Surrozen Provides First Quarter 2024 Financial Results and Business Update SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO 2024 demonstrate the promise of a Surrozen antibody based Wnt mimetic, to activate targeted cell regeneration in cornea endothelial dystrophies and dry e |
|
| April 25, 2024 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-278800 PROSPECTUS Up to 1,091,981 Shares of Common Stock Up to 40,000 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants Up to 11,136,106 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the proposed resale from time to time by the selling stockholders of: • Up to 1,091,981 shares of comm |
|
| April 23, 2024 |
April 23, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| April 23, 2024 |
United States securities and exchange commission logo April 23, 2024 Craig Parker President and Chief Executive Officer Surrozen, Inc. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy St |
|
| April 19, 2024 |
SRZN / Surrozen, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G 1 surrozen13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Surrozen, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86889P208 (CUSIP Number) April 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| April 18, 2024 |
As filed with the Securities and Exchange Commission on April 18, 2024 As filed with the Securities and Exchange Commission on April 18, 2024 Registration No. |
|
| April 18, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Com |
|
| April 17, 2024 |
SRZN / Surrozen, Inc. / COLUMN GROUP III GP, LP - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) SURROZEN, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86889P 208 (CUSIP Number) James Evangelista Chief Financial Officer The Column Group III, LP 1 Letterman Drive, Building D, Suite M-900 San Francisco, CA 9 |
|
| April 15, 2024 |
SRZN / Surrozen, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Surrozen, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 86889P208 (CUSIP Number) April 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| April 10, 2024 |
Exhibit 107 Calculation of Filing Fee Table (Form Type) Form S-8 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe |
|
| April 10, 2024 |
Exhibit 10.3 Surrozen, Inc. Stock Option Grant Notice (2021 Equity Incentive Plan) Surrozen, Inc. (the “Company”), pursuant to its 2021 Equity Incentive Plan (as may be amended and/or restated as of the Date of Grant set forth below, the “Plan”), has granted to Optionholder an option to purchase the number of shares of the Common Stock set forth below (the “Option”). The Option is subject to all o |
|
| April 10, 2024 |
Surrozen, Inc. 2021 Equity Incentive Plan Exhibit 10.2 Surrozen, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: August 14, 2021 Approved by the Stockholders: August 10, 2021 Adjusted for (1:15) Reverse Stock Split: December 13, 2023 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to e |
|
| April 10, 2024 |
Incentive Compensation Recoupment Policy Exhibit 97.1 Surrozen, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Surrozen, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) pro |
|
| April 10, 2024 |
Surrozen, Inc. 2021 Employee Stock Purchase Plan Exhibit 10.5 Surrozen, Inc. 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: August 14, 2021 Approved by the Stockholders: August 10, 2021 Adjusted for (1:15) Reverse Stock Split: December 13, 2023 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Commo |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| April 10, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 10, 2024 As filed with the U.S. Securities and Exchange Commission on April 10, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30-1374889 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ |
|
| April 8, 2024 |
SRZN / Surrozen, Inc. / COLUMN GROUP III GP, LP - SC 13D/A Activist Investment SC 13D/A 1 d768528dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) SURROZEN, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86889P 208 (CUSIP Number) James Evangelista Chief Financial Officer The Column Group III, LP 1 Letterman Drive, Building D, S |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 2, 2024 |
Exhibit 10.1 SURROZEN, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 1, 2024, by and between Surrozen, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). Whereas, subject to the terms an |
|
| April 2, 2024 |
Form of Series D Common Warrant Exhibit 10.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 2, 2024 |
Form of Series B Common Warrant Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 2, 2024 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 2, 2024 |
Exhibit 10.7 SURROZEN, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 1, 2024, by and between Surrozen, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securi |
|
| April 2, 2024 |
Form of Series C Common Warrant Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 2, 2024 |
SEC FILE NUMBER 001-39635 CUSIP NUMBERS 86889P208 86889P117 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 2, 2024 |
Form of Series A Common Warrant Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 1, 2024 |
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 Exhibit 99.1 Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 -Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events -Phase 1a data demonstrated target engagement, a pharmacodynamic effect and effects on liver function -Initiating Phase 1b proof-of-concept trial in severe alcohol-associated hepatitis - Expect to Present |
|
| April 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 1, 2024 |
Targeted Regeneration Corporate Presentation April 1, 2024 Exhibit 99.2 Legal Disclaimers © 2024 Surrozen, Inc. This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expr |
|
| February 14, 2024 |
SRZN / Surrozen, Inc. / Alyeska Investment Group, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2024 |
SRZN / Surrozen, Inc. / GOLDMAN SACHS GROUP INC Passive Investment SC 13G 1 SURROZEN.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SURROZEN, INC. - (Name of Issuer) Common Stock, par value $0.0001 per share - (Title of Class of Securities) 86889P208 - (CUSIP Number) December 29, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 7, 2024 |
SRZN / Surrozen, Inc. / BML Investment Partners, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* Surrozen, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 86889P109 (CUSIP Number) December 31, 2023 (Date |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 01, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 7, 2024 |
PROSPECTUS SUPPLEMENT NO.8 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 7, 2023) Registration No. 333-259496 Up to 1,972,157 Shares of Common Stock (Including up to 471,539 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,066,657 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated April 7, 2023 (as amended, |
|
| January 22, 2024 |
PROSPECTUS SUPPLEMENT NO.7 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 7, 2023) Registration No. 333-259496 Up to 1,972,157 Shares of Common Stock (Including up to 471,539 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,066,657 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated April 7, 2023 (as amended, |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 13, 2023 |
Certificate of Amendment to Certificate of Incorporation of Surrozen, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF SURROZEN, INC. Surrozen, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: FIRST: The name of this Company is Surrozen, Inc. SECOND: The original name of the Company was “Surrozen, Inc.”, and the date of filing the |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 13, 2023 |
PROSPECTUS SUPPLEMENT NO.6 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 7, 2023) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated April 7, 2023 (as amende |
|
| December 11, 2023 |
PROSPECTUS SUPPLEMENT NO.5 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 7, 2023) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated April 7, 2023 (as amende |
|
| December 11, 2023 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 30-1374889 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 8, 2023 |
Exhibit 10.2 Charles River Laboratories, Inc. 251 Ballardvale Street Wilmington, Massachusetts 01887 Distributed Bio, Inc. 329 Oyster Point Blvd., 3rd Floor South San Francisco, CA 94080 September 20, 2023 Re: Antibody Library Subscription Agreement between Surrozen Operating, Inc. and Charles River Laboratories Inc. (successor-in-interest to Distributed Bio, Inc), dated September 30, 2016, as ame |
|
| November 8, 2023 |
PROSPECTUS SUPPLEMENT NO.4 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 7, 2023) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated April 7, 2023 (as amende |
|
| November 8, 2023 |
Surrozen Provides Third Quarter 2023 Financial Results Exhibit 99.1 Surrozen Provides Third Quarter 2023 Financial Results Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical trial in healthy volunteers in Q1 2024 Initiating Phase 1b studies in 2024 for SZN-043 in severe alcoholic hepatitis and SZN-1326 in modera |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| November 8, 2023 |
Form of RSU Grant Package under 2021 Equity Incentive Plan Exhibit 10.1 Surrozen, Inc. Restricted Stock Unit Grant Notice (2021 Equity Incentive Plan) Surrozen, Inc. (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “RSU Award”). The RSU Award is subject to all of the term |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| October 24, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 13, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| October 13, 2023 |
Amended and Restated Bylaws of Surrozen, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SURROZEN, INC. (A DELAWARE CORPORATION) Table Of Contents Page ARTICLE I Offices 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II Corporate Seal 1 Section 3. Corporate Seal 1 ARTICLE III Stockholders’ Meetings 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings. 1 Section 6. Special Meetings. 5 Section 7. Notice of Meetings 6 |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 9, 2023 |
Surrozen Provides Second Quarter 2023 Financial Results SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 Corporate prioritization efforts expected to provide cash runway extension into 2025 SOUTH SAN FRANCISCO, Calif. |
|
| August 9, 2023 |
PROSPECTUS SUPPLEMENT NO.3 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 7, 2023) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated April 7, 2023 (as amende |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 19, 2023 |
Separation Agreement, by and between Surrozen Inc. and Dr. Wen-Chen Yeh, dated July 18, 2023 171 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 July 18, 2023 Wen-Chen Yeh 2920 Belmont Woods Way Belmont, CA 94002 [email protected] Dear Wen-Chen: This letter sets forth the substance of the separation agreement (the “Agreement”) that Surrozen Operating, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Comp |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 05, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 10, 2023 |
Exhibit 99.1 Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase 1a clinical trial in healthy volunteers with safety data expected by the end of 2023 SOUTH SAN FRA |
|
| May 10, 2023 |
424B3 1 srzn424b320230510q.htm 424B3 PROSPECTUS SUPPLEMENT NO.2 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 7, 2023) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the pros |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| May 10, 2023 |
Exhibit 10.2 Side Agreement No. 2 relating to the exclusive agreement between Surrozen Operating, Inc. and the Board of Trustees of the Leland Stanford Junior University, dated March 23, 2016, as amended THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Office of Technology Licensing 415 Broadway Street, 2nd Floor Redwood City, CA 94063 Attention: Sunita Rajdev, Director, Licensing an |
|
| April 7, 2023 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259496 PROSPECTUS Up to 31,612,348 Shares of Common Stock (Including up to 7,217,974 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,323 Warrants to Purchase Common Stock This prospectus relates to the issuance by us of an aggregate of up to 7,217,974 shares of our common stock, $0.0001 par value p |
|
| April 7, 2023 |
PROSPECTUS SUPPLEMENT NO.1 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 7, 2023) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated April 7, 2023 (as amende |
|
| April 6, 2023 |
Up to 7,003,383 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-263923 PROSPECTUS Up to 7,003,383 Shares of Common Stock This prospectus relates to the issuance by us of an aggregate of up to 7,003,383 shares of our common stock, $0.0001 par value per share, or the Common Stock, by Lincoln Park Capital Fund, LLC, or the Selling Securityholder. The shares included in this prospectus consist |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| April 6, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 05, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 31, 2023 |
EXHIBIT 21.1 SURROZEN, INC. List of Subsidiaries Subsidiary Jurisdiction of Incorporation Surrozen Operating, Inc. Delaware Surrozen Netherlands, B.V. Amsterdam |
|
| March 31, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Surrozen, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share, 2021 Equity Incentive Plan 457(c) 457(h) 1,994,609 (2) $0. |
|
| March 31, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2023 As filed with the U.S. Securities and Exchange Commission on March 31, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 98-1556622 ( State or other jurisdiction of incorporation or organization) (I.R.S. Emplo |
|
| March 31, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2023. POS AM Table of Contents As filed with the U.S. Securities and Exchange Commission on March 31, 2023. Registration No. 333-263923 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SURROZEN, INC. (Exact name of registrant as specified in its charter) Delaware 2834 98- |
|
| March 31, 2023 |
Exhibit 4.6 AMENDED AND RESTATED WARRANT AGREEMENT by and between SURROZEN, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY As amended on March 31, 2023 THIS AMENDED AND RESTATED WARRANT AGREEMENT (this “Agreement”), dated March 31, 2023, is by and between Surrozen, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust co |
|
| March 31, 2023 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on March 31, 2023. Registration No. 333-259496 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SURROZEN, INC. (Exact name of registrant as specified in its charter) Delaware 2834 98-1556622 (State or o |
|
| March 31, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-268745 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 21, 2022) $8,970,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated December 21, 2022, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-268745), or the Prior Prosp |
|
| March 31, 2023 |
Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary description of the securities of Surrozen, Inc. and is based on the provisions of our Certificate of Incorporation, or the Certificate of Incorporation, our Bylaws, or the Bylaws, and the applicable provisions of the Delaware General Corporation |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 23, 2023 |
PROSPECTUS SUPPLEMENT NO.6 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated March 31, 2022) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated March 31, 2022 (as amen |
|
| March 23, 2023 |
Up to 7,003,383 Shares of Common Stock PROSPECTUS SUPPLEMENT NO.6 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 5, 2022) Registration No. 333-263923 Up to 7,003,383 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated April 5, 2022 (as amended, the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (No. 333-263923). This prospectus supplement is being |
|
| March 22, 2023 |
Exhibit 99.1 Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 14, 2023 |
SRZN / Surrozen, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2023 |
SRZN / Surrozen, Inc. / COLUMN GROUP III GP, LP - SC 13D/A Activist Investment SC 13D/A 1 d460852dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) SURROZEN, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86889P 109 (CUSIP Number) James Evangelista Chief Financial Officer The Column Group III, LP 1 Letterman Drive, Building D, S |
|
| February 2, 2023 |
SRZN / Surrozen, Inc. / REGENTS OF THE UNIVERSITY OF CALIFORNIA - SC13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Surrozen Inc. (Name of Issuer) Common Stock, $0.0001 (Title of Class of Securities) 86889P109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 2, 2023 |
SRZN / Surrozen, Inc. / BML Investment Partners, L.P. - NONE Passive Investment SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Surrozen, Inc./DE (Name of Issuer) Common Stock, $0.0001 (Title of Class of Securities) 86889P109 (CUSIP Number) January 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 5, 2023 |
PROSPECTUS SUPPLEMENT NO.5 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated March 31, 2022) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated March 31, 2022 (as amen |
|
| January 5, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 04, 2023 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 5, 2023 |
Up to 7,003,383 Shares of Common Stock PROSPECTUS SUPPLEMENT NO.5 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 5, 2022) Registration No. 333-263923 Up to 7,003,383 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated April 5, 2022 (as amended, the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (No. 333-263923). This prospectus supplement is being |
|
| December 21, 2022 |
424B5 1 d419980d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268745 PROSPECTUS $22,875,000 Common Stock We have entered into a sales agreement with Guggenheim Securities, LLC, or Guggenheim Securities, dated December 9, 2022, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus |
|
| December 15, 2022 |
CORRESP 1 filename1.htm SURROZEN, INC. 171 Oyster Point Blvd., Suite 400 South San Francisco, California 94080 December 15, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford RE: Surrozen, Inc. Registration Statement on Form S-3 File No. 333-268745 Acceleration Request Requested Date: December |
|
| December 15, 2022 |
SURROZEN, INC. SECURITIES PURCHASE AGREEMENT EX-99.1 Exhibit 99.1 SURROZEN, INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into as of December 12, 2022, by and between SURROZEN, INC., a Delaware corporation (the “Company”), and each of the entities set forth on Exhibit A hereto (each a “Seller” and collectively, the “Sellers”). RECITALS: WHEREAS, the Sellers collectively are the record own |
|
| December 15, 2022 |
SRZN / Surrozen, Inc. / Consonance Capital Management LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Surrozen, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 86889P109 (CUSIP NUMBER) Kevin Livingston 1370 Avenue of the Americas, 33rd Floor New York, NY 10019 (212) 660-8060 (Name, Address and Telep |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 15, 2022 |
United States securities and exchange commission logo December 15, 2022 Craig Parker President and Chief Executive Officer Surrozen, Inc. |
|
| December 15, 2022 |
Up to 7,003,383 Shares of Common Stock PROSPECTUS SUPPLEMENT NO.4 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 5, 2022) Registration No. 333-263923 Up to 7,003,383 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated April 5, 2022 (as amended, the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (No. 333-263923). This prospectus supplement is being |
|
| December 15, 2022 |
PROSPECTUS SUPPLEMENT NO.4 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated March 31, 2022) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated March 31, 2022 (as amen |
|
| December 9, 2022 |
Exhibit 4.4 SURROZEN, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section 2.03 |
|
| December 9, 2022 |
Exhibit 1.2 SURROZEN, INC. SALES AGREEMENT December 9, 2022 Guggenheim Securities, LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), Surrozen, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell from time to time through Guggenheim Securities, LLC (the ?Agent?), as sales agent, shares of the Company?s com |
|
| December 9, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 SURROZEN, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF SURROZEN, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SURROZEN, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [?] and hav |
|
| December 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Ca |
|
| December 9, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 SURROZEN, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF SURROZEN, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SURROZEN, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [? |
|
| December 9, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 SURROZEN, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF SURROZEN, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SURROZEN, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [? |
|
| December 9, 2022 |
As filed with the Securities and Exchange Commission on December 9, 2022 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 9, 2022 Registration No. |
|
| November 16, 2022 |
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 14, 2022 (GLOBE NEWSWIRE) - Surrozen, Inc. (?Surrozen? or the ?Company?) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter |
|
| November 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 15, 2022 |
PROSPECTUS SUPPLEMENT NO.3 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated March 31, 2022) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated March 31, 2022 (as amen |
|
| November 15, 2022 |
Up to 7,003,383 Shares of Common Stock PROSPECTUS SUPPLEMENT NO.3 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 5, 2022) Registration No. 333-263923 Up to 7,003,383 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated April 5, 2022 (as amended, the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (No. 333-263923). This prospectus supplement is being |
|
| November 14, 2022 |
Exhibit 10.1 Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN BOEHRINGER INGELHEIM INTERNATIONAL GMBH Binger Strasse 173, 55216 Ingelheim am Rhein AND Surrozen OPERATING, INC. 171 Oyster Po |
|
| November 14, 2022 |
Exhibit 4.7 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary description of the securities of Surrozen, Inc. and is based on the provisions of our Certificate of Incorporation, or the Certificate of Incorporation, our Bylaws, or the Bylaws, and the applicable provisions of the Delaware General Corporation |
|
| November 14, 2022 |
Exhibit 4.6 WARRANT AGREEMENT by and between CONSONANCE-HFW ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated August 11, 2021 THIS WARRANT AGREEMENT (this ?Agreement?), dated August 11, 2021, is by and between Consonance-HFW Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust com |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| October 6, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 25, 2022 |
Up to 7,003,383 Shares of Common Stock PROSPECTUS SUPPLEMENT NO.2 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 5, 2022) Registration No. 333-263923 Up to 7,003,383 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated April 5, 2022 (as amended, the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (No. 333-263923). This prospectus supplement is being |
|
| August 23, 2022 |
PROSPECTUS SUPPLEMENT NO.2 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated March 31, 2022) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated March 31, 2022 (as amen |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 11, 2022 |
Surrozen Reports Second Quarter 2022 Financial Results Exhibit 99.1 Surrozen Reports Second Quarter 2022 Financial Results ? Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoing ? Preclinical proof-of-concept data for multiple programs presented and published in Q2 continue to validate Wnt modulation for tissue repair SOUTH SAN FRANCISCO, Calif., August 11, 2022 (GLOBE NEWSWIRE) - Surrozen, Inc. (?Surrozen? or the ?Company?) (Nasdaq: |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| June 14, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 12, 2022 |
PROSPECTUS SUPPLEMENT NO.1 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated March 31, 2022) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement updates and supplements the prospectus dated March 31, 2022 (as amen |
|
| May 12, 2022 |
Up to 7,003,383 Shares of Common Stock PROSPECTUS SUPPLEMENT NO.1 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated April 5, 2022) Registration No. 333-263923 Up to 7,003,383 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated April 5, 2022 (as amended, the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (No. 333-263923). This prospectus supplement is being |
|
| May 11, 2022 |
Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is of the type that the registrant treats as private or confidential. This redacted information has been marked in this exhibit with three asterisks [***]. NON-EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and SURROZEN OPERATING, INC. for Wnt Modulat |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 11, 2022 |
Exhibit 99.1 Surrozen Reports First Quarter 2022 Financial Results On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) - Surrozen, Inc. (?Surrozen? or the ?Company?) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for t |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. |
|
| May 10, 2022 |
SRZN / Surrozen, Inc. / Ugwumba Chidozie - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Under the Securities Exchange Act of 1934 (AMENDMENT NO.) Surrozen, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 86889P10 |
|
| April 28, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2022 |
DEFA14A 1 ny20003206x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 5, 2022 |
Up to 7,003,383 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-263923 PROSPECTUS Up to 7,003,383 Shares of Common Stock This prospectus relates to the issuance by us of an aggregate of up to 7,003,383 shares of our common stock, $0.0001 par value per share (the ?Common Stock?), by Lincoln Park Capital Fund, LLC (the ?Selling Securityholder?). The shares included in this prospectus consist of shares of Comm |
|
| April 1, 2022 |
SURROZEN, INC. 171 Oyster Point Blvd., Suite 400 South San Francisco, California 94080 April 1, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes RE: Surrozen, Inc. Registration Statement on Form S-1 File No. 333-263923 Acceleration Request Requested Date: April 5, 2022 Requested Time: 4:00 p.m. E |
|
| April 1, 2022 |
United States securities and exchange commission logo April 1, 2022 Craig Parker President and Chief Executive Officer Surrozen, Inc. |
|
| March 31, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259496 PROSPECTUS Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus relates to the issuance by us of an aggregate of up to 7,217,991 shares of our common stock, $0.0001 par value per sha |
|
| March 29, 2022 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on March 2 9 , 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SURROZEN, INC. (Exact name of registrant as specified in its charter) Delaware 2834 98-1556622 (State or other jurisdiction of incorporation or |
|
| March 29, 2022 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on March 2 9 , 2022. Registration No. 333-259496 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SURROZEN, INC. (Exact name of registrant as specified in its charter) Delaware 2834 98-1556622 (State or |
|
| March 29, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value pe |
|
| March 29, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 29, 2022 As filed with the U.S. Securities and Exchange Commission on March 29, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SURROZEN, INC. (Exact name of registrant as specified in its charter) Delaware 98-1556622 (State or other jurisdiction of incorporation or organization) (I.R.S. Empl |
|
| March 29, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value p |
|
| March 28, 2022 |
EXHIBIT 21.1 SURROZEN, INC. List of Subsidiaries Subsidiary Jurisdiction of Incorporation Surrozen Operating, Inc. Delaware |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. |
|
| March 28, 2022 |
Exhibit 10.20 LEASE THE COVE AT OYSTER POINT HCP OYSTER POINT III LLC, a Delaware limited liability company as Landlord, and SURROZEN, INC., a Delaware corporation, as Tenant. TABLE OF CONTENTS Page 1. PREMISES, BUILDING, PROJECT, AND COMMON AREAS 3 2. LEASE TERM; OPTION TERM 5 3. BASE RENT 7 4. ADDITIONAL RENT 7 5. USE OF PREMISES 12 6. SERVICES AND UTILITIES 16 7. REPAIRS 18 8. ADDITIONS AND ALT |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 24, 2022 |
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 SOUTH SAN FRANCISCO, Calif. |
|
| February 24, 2022 |
PROSPECTUS SUPPLEMENT NO.3 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated November 9, 2021) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus, dated November 9, 2021 (as amended, th |
|
| February 24, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of February 18, 2022, is made by and between SURROZEN, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined herein sha |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 24, 2022 |
Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of February 18, 2022, is made by and between SURROZEN, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subject to the ter |
|
| February 14, 2022 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Surrozen, Inc.is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2022 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its general |
|
| February 14, 2022 |
SRZN / Surrozen, Inc. / GLAZER CAPITAL, LLC Passive Investment SC 13G/A 1 chfw20211231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Surrozen, Inc. formerly known as Consonance-HFW Acquisition Corp. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) G2445M129 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this |
|
| February 14, 2022 |
SRZN / Surrozen, Inc. / BRIDGER MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
SRZN / Surrozen, Inc. / BAKER BROS. ADVISORS LP - SCHEDULE 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2022 |
SRZN / Surrozen, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| January 27, 2022 |
SRZN / Surrozen, Inc. / REGENTS OF THE UNIVERSITY OF CALIFORNIA - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Surrozen Inc. (Name of Issuer) Common Stock, $0.0001 (Title of Class of Securities) 86889P109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Surrozen, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39635 98-1556622 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 10, 2022 |
PROSPECTUS SUPPLEMENT NO.2 Filed Pursuant to Rule 424(b)(3) (To the Prospectus dated November 9, 2021) Registration No. 333-259496 Up to 31,612,349 Shares of Common Stock (Including up to 7,217,991 Shares of Common Stock Issuable Upon Exercise of Warrants) Up to 4,151,324 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus, dated November 9, 2021 (as amended, th |
